

Edgar Filing: ENDOREX CORP - Form 425

ENDOREX CORP
Form 425
September 05, 2001

Filed by Endorex Corporation pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed to be filed pursuant to Rule 14a-12 of the Securities Exchange act of 1934, as amended.

Subject: Corporate Technology Development, Inc.
Commission File No. 1-14778

ON September 5, 2001, ENDOREX CORPORATION, A DELAWARE CORPORATION GAVE THE FOLLOWING PRESENTATION:

ORAL DELIVERY OF DRUGS

WELCOME TO A BRAVE NEW WORLD OF NO MORE NEEDLES

[Photographic image depicting a hand holding a syringe.]

Michael Rosen
President & CEO
Endorex Corporation
(AMEX: DOR)

Wells Fargo Van Kasper
"The Class of 2001"
Conference

September 5, 2001

FORWARD-LOOKING STATEMENTS:
SECURITIES LAW LEGENDS

This presentation contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of known and unknown risks and uncertainties. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, Endorex cannot assure you that it will be able to successfully develop or commercialize products based on Endorex's technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that Endorex's technologies will prove to be safe and effective, that Endorex's cash expenditures will be at projected levels, that Endorex will be able to obtain future financing or funds, that Endorex or its joint ventures or its collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that Endorex's joint ventures or its collaborations with other companies will continue, that Endorex's business strategy will be successful or that Endorex will be able to carry out our plans for 2001 and beyond. This presentation also contains forward-looking statements regarding Endorex's, Corporate Technology Development, Inc.'s, or CTD, and the combined companies' plans, expectations, intentions and strategies. These statements include forward-looking statements

Edgar Filing: ENDOREX CORP - Form 425

about Endorex's, CTD's and the combined companies' products, product development and product pipeline. These statements are not guarantees of future performance or results and actual results could differ materially from current expectations. Factors that could cause or contribute to such differences include, but are not limited to, product integration risk, the possibility that the operations and management of Endorex and CTD will not be successfully integrated, the possibility that the merger might not be consummated, the effects of the public announcement on the progress of certain drug development projects and that benefits sought to be achieved by the transaction will not be achieved. Furthermore, Endorex, CTD, and the combined companies cannot assure you that they will be able to successfully develop or commercialize products based on their technology, particularly in light of the significant uncertainty inherent in developing drug and drug delivery products, conducting clinical trials and obtaining regulatory approvals, that their technologies will prove to be safe and effective, that their cash expenditures will be at projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that they will be able to successfully patent, register or protect their technology, trademarks and products, or that the business strategies of Endorex, CTD, or the combined companies will be successful. In addition to the matters described in this presentation, risk factors as described from time to time in Endorex's filings with the Securities and Exchange Commission, including, but not limited to, our most recent reports on Form 10-QSB, Form 10-KSB, as amended, and our Registration Statement on Form S-3, as amended, may affect our financial results. We assume no obligation to update the information in this release.

FORWARD-LOOKING STATEMENTS: SECURITIES LAW LEGENDS

Additional Information and Where to Find It: It is expected that Endorex will file a Registration Statement on SEC Form S-4 and Endorex and CTD will file a Joint Proxy Statement/Prospectus with the SEC in connection with the transaction, and that Endorex and CTD will mail a Joint Proxy statement/Prospectus to stockholders of Endorex and CTD containing information about the transaction. Investors and security holders are urged to read the Registration Statement and the Joint Proxy Statement/Prospectus carefully when they are available. The Registration Statement and the Joint Proxy Statement/Prospectus will contain important information about Endorex, CTD, the transaction, the persons soliciting proxies relating to the transaction, their interests in the transaction and related matters. Investors and security holders will be able to obtain free copies of these documents through the website maintained by the SEC at <http://www.sec.gov>. Free copies of the Joint Proxy Statement/Prospectus and these other documents may also be obtained from Endorex by directing a request by mail to Endorex at 28101 Ballard Drive, Suite F, Lake Forest, IL 60045-4544, telephone (847) 573-8990, or from CTD by directing a request by mail to CTD at 1680 Michigan Avenue, Suite 700, Miami, Florida 33139, telephone 305-777-2258.

In addition to the Registration Statement and the Joint Proxy Statement/Prospectus, Endorex files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Endorex at the SEC public reference rooms at 450 Fifth Street, N.W., Washington, D.C. 20549 or at any of the SEC's other public reference rooms in New York, New York and Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms.

Edgar Filing: ENDOREX CORP - Form 425

Endorex's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at <http://www.sec.gov>.

Endorex, CTD, directors and certain executive officers of Endorex and CTD, Paramount Capital, Inc. and certain affiliates and employees of Paramount Capital, Inc., may be considered participants in the solicitation of proxies in connection with the merger. Certain directors and executive officers may have direct or indirect interests in the merger due to securities holdings of Endorex and CTD and rights to bonus payments following the merger. Paramount Capital, Inc. and certain affiliates and employees of Paramount Capital, Inc. may be paid to solicit proxies in connection with the merger and may have direct or indirect interests in the merger due to their securities holdings of Endorex and CTD. In addition, certain directors and officers, after the merger, will be indemnified by Endorex and will benefit from insurance coverage for liabilities that may arise from their service as directors and officers of CTD prior to the merger. Additional information regarding the participants in the solicitation will be contained in the Joint Proxy Statement/Prospectus to be filed by Endorex and CTD with the SEC.

ENDOREX PROFILE

- Oral drug delivery technology addresses significant markets:
 - Biotech injectable products - \$18.5 billion
 - Other drugs with delivery issues
- Business strategy for extending patent and commercial life of existing drugs via new delivery systems
- Strong intellectual property portfolio: 50+ issued patents
- New company acquisition strengthens drug pipeline, balance sheet and management team

THE ADVANTAGE OF ORAL DELIVERY

- For the Patient:
 - improved quality of life
 - convenience
 - compliance

THE PAIN OF INJECTIONS

- 4 million U.S. children receive up to 21 vaccine inoculations every 2 years

Edgar Filing: ENDOREX CORP - Form 425

- 1 million U.S. insulin-dependent diabetics get 2-3 shots daily for life

CDC/American Diabetes Association data

[Photograph image depicting a mother comforting a crying child receiving an injection via syringe.]

NEEDLE-PHOBIA AND THE IMPACT ON COMPLIANCE!

- 50 million Americans get annual "flu" shots
- 66% of patients receiving the Hepatitis B vaccine don't complete 3-shot regimen

Frost & Sullivan/CDC data

[Photographic image depicting an elderly woman receiving an injection via syringe.]

THE ADVANTAGE OF ORAL DELIVERY

- For the Patient:
 - improved quality of life
 - convenience
 - compliance
- For the Healthcare System:
 - reduced costs

THE COST OF ADMINISTERING INJECTIONS!

| THE COST OF ADMINISTERING INJECTIONS* | |
|--|-----|
| MEDICAL PERSONNEL | 65% |
| TRAINING | 8% |
| VACCINE | 10% |
| REFRIGERATION | 10% |
| SYRINGE | 7% |

CDC Data

Edgar Filing: ENDOREX CORP - Form 425

- Medical Personnel
- Training
- Vaccine
- Refrigeration
- Syringe

THE ADVANTAGE OF ORAL DELIVERY

- For the Patient:
 - improved quality of life
 - convenience
 - compliance
- For the Healthcare System:
 - reduced costs
- For Administering Drugs into the Body:
 - molecular size/weight
 - solubility in water
 - "fragility" in the gastrointestinal tract

PROTEIN/PEPTIDE DRUG DELIVERY

| MOLECULAR WEIGHT | DRUGS |
|---------------------|---|
| VERY HIGH >50 KD | Vaccines (50 - 1000 KD) Monoclonal antibodies (150 KD) |
| HIGH 21- 50 KD | Human Growth Hormone (22 KD) Erythropoietin (30 KD) |
| MEDIUM 6 - 20 KD | Insulin (6 KD) Heparins (6-30 KD) Interferons (20 KD) Colony Stimulating Factors (19 KD) |
| LOW .5 - 5 KD | LHRH (1 KD) Calcitonin (3- 4 KD) Other Peptides |

BIOTECH INJECTABLE PRODUCTS MARKET
(PROTEINS/PEPTIDES)
\$18.5 BILLION

Edgar Filing: ENDOREX CORP - Form 425

(2001E - S. G. COWEN)

[Graphic of a circular chart sectioned into different categories setting forth the different product markets making up the overall estimated injectable products market for the year 2001, consisting of: (a) growth factors, (b) hormones (c) vaccines, (d) cytokines (e) gene therapy and (f) others.]

LEADING BIOTECH INJECTABLE PRODUCTS

| Product: ----- | Worldwide 2001 E Sales (\$B) ----- |
|---|---------------------------------------|
| 1. Insulin | \$3.6 |
| 2. Erythropoietin | \$3.1 |
| 3. Vaccines | \$3.0 |
| 4. Interferons | \$1.8 |
| 5. Monoclonal antibodies | \$1.7 |
| 6. Colony stimulating factors | \$1.4 |
| 7. Heparins | \$1.0 |
| 8. Growth Hormones | \$0.9 |
| 9. LHRH Analogues | \$0.9 |
| 10. Interleukins | \$0.3 |
| 11. Other (gene therapy, antisense, blood factors, etc) | \$0.9 |
| | ----- |
| | \$18.5 |

S.G. Cowen data

ENDOREX ORAL DELIVERY TECHNOLOGIES LIPID-BASED SYSTEMS

[Image of a microscopic photograph depicting polymerized liposomes.]

- Initial technology developed by DR. ROBERT LANGER at Massachusetts Institute of Technology
- Platform capability for DRUGS and VACCINES
- Suitable for ORAL and NASAL delivery
- Capable of delivering range of "drug payloads"
- Protects "payload" through the gastrointestinal tract without altering drug structure
- Scaleable

Edgar Filing: ENDOREX CORP - Form 425

THE ORASOME(TM) ORAL DELIVERY SYSTEM

[Graphic depicting the Orasome(TM) oral delivery system consisting of a drawing of a water soluble drug encapsulated by a lipid bilayer.]

ORAL DELIVERY PROCESS

POTENTIAL ADVANTAGES OF ENDOREX ORAL DRUG DELIVERY TECHNOLOGY

- Patient
 - easier delivery format (liquid/pill)
- Physician
 - patient compliance with therapy
- Pharmaceutical Company/Partner
 - differentiated product form
 - extended product patent life
 - suitable for water soluble and insoluble drugs

PRODUCTS UNDER DEVELOPMENT

| ORAL PRODUCT CANDIDATES | Injectable Market* |
|-------------------------------|--------------------|
| - Human growth hormone | \$1.7 billion |
| - Insulin | \$3.6 billion |
| - Influenza vaccine | \$1.0 billion |
| - Tetanus vaccine | \$50 million |
| - Other protein/peptide drugs | \$1.3 billion |
| - Other water insoluble drugs | \$1.6 billion |

*Frost & Sullivan
S.G. Cowen

ENDOREX BUSINESS STRATEGY

Edgar Filing: ENDOREX CORP - Form 425

[Graphical image of a flow chart setting forth the business strategy of Endorex with the following steps: (a) pharma companies to (b) new or approved injectable drug/vaccine to (c) Endorex oral delivery systems to (e) new oral product & patent.]

Revenue Stream:

-
- License and development fees
 - Milestone fees
 - Royalties

COMPETITIVE ARENA

* CDC DATA

COMPETITIVE ARENA PROTEIN & PEPTIDE DELIVERY

IMPLANTS

Alkermes
Alza
Atrix

PULMONARY

Aerogen
Aradigm
Elan/Dura
Inhale Therapeutics

TRANSDERMAL

Bioject
Powerderject

NASAL

Aviron
ID Biomedical
West Pharm.

ORAL

Emisphere
Endorex
Generex
Nobex
Unigene

ISSUES FOR ENDOREX GROWTH

- Expanding drug delivery technology focus to include small molecules:
 - macromolecular delivery challenges
- Creating a drug pipeline spanning clinical and preclinical development

Edgar Filing: ENDOREX CORP - Form 425

- Having a product closer to market (phase 3)
- Obtaining additional financial resources to take product to market

STRATEGIC RATIONALE FOR CTD ACQUISITION

Products

- 1 - Phase 3
- 1 - Phase 1-2

STRATEGIC RATIONALE FOR CTD ACQUISITION

| Products | Intellectual Property |
|---------------|-----------------------|
| 1 - Phase 3 | 8 Patents |
| 1 - Phase 1-2 | 10 Pending |
| | Orphan drug |

STRATEGIC RATIONALE FOR CTD ACQUISITION

Financial

\$5M
No debt

| Products | Intellectual Property |
|---------------|-----------------------|
| 1 - Phase 3 | 8 Patents |
| 1 - Phase 1-2 | 10 Pending |
| | Orphan drug |

STRATEGIC RATIONALE FOR CTD ACQUISITION

| | |
|------------------------------|-------------------------------------|
| Financial \$5M No debt | Management Board Chairman/CEO |
| Products | Intellectual Property |

Edgar Filing: ENDOREX CORP - Form 425

| | |
|---------------|-------------|
| 1 - Phase 3 | 8 Patents |
| 1 - Phase 1-2 | 10 Pending |
| | Orphan drug |

CORPORATE TECHNOLOGY DEVELOPMENT, INC

Profile:

- Founded in 1998
- HQ in Miami
- Privately-held specialty pharmaceutical company
- Key Investors:
 - TVM Techno Venture Management
 - Nomura Bank
 - Paul Capital Partners

CORPORATE TECHNOLOGY DEVELOPMENT, INC.
KEY PRODUCTS

orBec (R) (beclomethasone dipropionate): corticosteroid

| | Current (Glaxo/Beconase) ----- | CTD --- |
|-------------------------|--|---|
| Formulation: | Pulmonary/nasal (Beconase (R) /Glaxo) | Oral tablets (dual |
| Therapeutic Indication: | Asthma | Treatment of Intes Graft vs. Host Dise other gastro disord |
| Development Status: | Marketed | Phase 3 multicenter Orphan drug/FDA "fast-track designa |
| Market: | \$500 M/year | 2500-5100 patients/ (15-30% of allogene marrow transplant p |

CORPORATE TECHNOLOGY DEVELOPMENT, INC
KEY PRODUCTS

Edgar Filing: ENDOREX CORP - Form 425

Oraprine(R) (azathioprine): immunosuppressant

| | Current (Faro/Imuran (R)) ----- | CTD --- |
|-------------------------|---|---|
| Formulation: | I.V./Tablet | Oral (liquid) |
| Therapeutic Indication: | Treatment of: - transplant rejection - rheumatoid arthritis | Same Oral GVHD |
| Development Status: | Marketed | Phase 1 bioequivalency trial Phase 1/2 trial for chronic oral autoimmune diseases completed; Orphan drug |

ENDOREX/CTD PRODUCT PIPELINE

[Graphical image of a chart depicting product candidates of Endorex and CTD with arrows indicating the different stages of development for the following product candidates:

orBec (TM)

- I GVHD [arrow indicates initial Phase 3 development stage]
- Other GI Disorders [arrow indicates development stage between Phase 1 and Phase 2]

Oraprine (R)

- Oral autoimmune disorders [arrow indicates development stage between Phase 1 and Phase 2]
- Rheumatoid arthritis/transplant [arrow indicates Initial Phase 1 development stage]

Oral Delivery

- Insulin [arrow indicates development stage between research and preclinical]
- Human Growth Hormone [arrow indicates development stage between research and preclinical]
- Tetanus Vax [arrow indicates development stage between research and preclinical]
- Influenza Vax [arrow indicates development stage between research and preclinical]
- Other Drugs [arrow indicates research development stage]

ACQUISITION OF CTD

- Endorex to acquire CTD for 10 million shares:

Edgar Filing: ENDOREX CORP - Form 425

- 9.4 million common shares
- .6 million warrants/options
- Endorex to integrate CTD management/board:
 - 3 members to join Endorex board
 - Chairman Colin Bier, Ph.D., to assume position of Endorex Chairman/CEO

ENDOREX CAPITAL STRUCTURE POST ACQUISITION

| | Shares - Millions | |
|--------------------------|-------------------|---------------|
| | Outstanding | Fully-Diluted |
| Endorex | 12.7 | 19.8 |
| Endorex + CTD | 22.1 | 29.8 |
| CTD ownership of Endorex | 44% | 33% |

SYNERGY OF COMPANIES

Oral/Mucosal Delivery

ENDOREX
 MACROMOLECULES
 PRECLINICAL
 hGH
 Insulin
 Vaccines
 Other
 Management
 Public

\$9.5M cash

CTD
 SMALL MOLECULES
 CLINICAL
 orBec (TM)
 phase 3
 Oraprime (R)
 phase 1-2
 Management
 Private

\$5.0M cash

Edgar Filing: ENDOREX CORP - Form 425

ENDOREX ORAL/MUCOSAL DELIVERY

Endorex

CTD

- Clinical/preclinical pipeline
- Expanded patent portfolio
- Enhanced management
- Strengthened balance sheet

ENDOREX HIGHLIGHTS

- Oral drug delivery technology addresses significant market:
 - Biotech injectable products - \$18.5 billion
 - Other drugs with delivery issues
- Business strategy for extending patent and commercial life of existing drugs via new delivery systems
- Strong intellectual property portfolio: 50+ issued patents
- New company acquisition strengthens drug pipeline, balance sheet and management team

THANK YOU

WELCOME TO A BRAVE NEW WORLD OF NO MORE NEEDLES

[Photographic image depicting a hand holding a syringe.]